RxSight, Inc.
NASDAQ:RXSTMedical - Devices
+$0.05 today
- Market cap
- $210.07M
- Beta
- 1.13
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$1.13
Volume 0.74M
Average 0.80M
RXST Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
RxSight, Inc.NASDAQ: RXST
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $936K, compared with -$928K a year earlier. Trailing-twelve-month accounts receivables was $8.52M.
Context
- Accounts receivables amounted to 4.9% of revenue in FY2025, down 2.1 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $936K or moves back toward the trailing-twelve-month quarterly average of $2.13M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 6.66M USD
- Year-over-year change
- +167.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.66M | +167.9% |
| FY2024 | 2024-12-31 | (9.8M) | -5.1% |
| FY2023 | 2023-12-31 | (9.33M) | -53.0% |
| FY2022 | 2022-12-31 | (6.09M) | -205.3% |
| FY2021 | 2021-12-31 | (2M) | — |
Accounts Receivables vs competitors
How RXST compares with its peers on the latest reported figures
- RXST's LTM Mar 2026 accounts receivables of $8.52M is the largest of the 9 companies compared; the peer median is $1.7M.
- Its year-over-year change of +190.0% is the highest of 9, against a peer median of -11.6%.
- Accounts receivables amounts to 6.7% of revenue for RXST, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.52M | +190.0% | — | 6.7% | |
| LTM Mar 2026 | $8.05M | +8.8% | +33.0% | 3.3% | |
| LTM Mar 2026 | $6.2M | -10.1% | +30.2% | 6.0% | |
| LTM Mar 2026 | $3.42M | -129.1% | -78.6% | 1.0% | |
| LTM Mar 2026 | $3.19M | -13.2% | -65.0% | 1.4% | |
| LTM Mar 2026 | $647K | +117.0% | +67.3% | 0.7% | |
| LTM Mar 2026 | $306K | +107.3% | -42.6% | 0.1% | |
| LTM Mar 2026 | $217K | -98.2% | +38.4% | 0.2% | |
| LTM Mar 2026 | $49.73K | -134.1% | — | — | |
| Peer median (excluding RXST) | $1.7M | -11.6% | +30.2% | 1.0% | |
Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.69M) | (66.76M) | (48.61M) | (27.46M) | (38.94M) |
| Depreciation & Amortization | 3.99M | 4.02M | 4.24M | 3.62M | 3.27M |
| Deferred Income Tax | (5.4M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.58M | 11.4M | 15.75M | 24.64M | 31.61M |
| Change in Working Capital | (2.68M) | (7.41M) | (9.07M) | (9.21M) | (4.89M) |
| Accounts Receivables | (2M) | (6.09M) | (9.33M) | (9.8M) | 6.66M |
| Inventory | (2.11M) | (7.56M) | (2.75M) | (4.99M) | (11.48M) |
| Accounts Payables | 555K | 635K | 1.25M | 946K | 627K |
| Other Working Capital | 874K | 5.6M | 1.75M | 4.64M | (692K) |
| Other Non-Cash Items | 493K | (101K) | (3.9M) | (8.54M) | (6.55M) |
| Operating Cash Flow | (44.71M) | (58.85M) | (41.59M) | (16.95M) | (15.51M) |
| Capital Expenditures | (1.94M) | (2.39M) | (4.81M) | (5.44M) | (3.83M) |
| Acquisitions (Net) | 79.97M | (42.34M) | 17.32M | 0 | 0 |
| Purchases of Investments | (159.97M) | (212.66M) | (272.32M) | (336.87M) | (239.28M) |
| Sales of Investments | 80M | 255M | 255M | 243M | 260M |
| Other Investing Activities | (79.97M) | 42.34M | (17.32M) | 0 | 0 |
| Investing Cash Flow | (81.91M) | 39.95M | (22.13M) | (99.31M) | 16.89M |
| Debt Repayment | 14.97M | (121K) | (40.15M) | (61K) | (26K) |
| Common Stock Issued | 121.14M | 7.83M | 105.96M | 128.92M | 3.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.23M | (1.38M) | (4.28M) | (5.54M) | (2.06M) |
| Financing Cash Flow | 137.34M | 6.33M | 61.52M | 123.32M | 1.86M |
| Effect of Forex Changes | (10K) | (9K) | 6K | (9K) | 2K |
| Net Change in Cash | 10.72M | (12.58M) | (2.19M) | 7.05M | 3.24M |
| Free Cash Flow | (46.65M) | (61.24M) | (46.41M) | (22.39M) | (19.34M) |
RxSight, Inc.
NASDAQ:RXST
Intrinsic Alpha fair value
Locked
Current Price
$5.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.